References
- Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
- Oates T, Cross J, Davenport A. Cost comparison of online hemodiafiltration with high-flux hemodialysis. J Nephrol. 2012;25(2):192–197
- Okuno S, Ishimura E, Kohno K, et al. Serum beta2-microglobulin level is a significant predictor of mortality in maintenance hemodialysis patients. Nephrol Dial Transplant. 2009;24:571–577
- Locatelli F, Cavalli A, Manzoni C, Pontoriero G. The membrane permeability outcome study. Contrib Nephrol. 2011;175:81–92
- Merlo J, Wessling A, Melander A. Comparison of dose standard units for drug utilization studies. Eur J Clin Pharmacol. 1996;50:27–30
- Locatelli F, Martin-Malo A, Hannedouche T, et al. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol. 2009;20:645–654
- Koda Y. Clinical outcomes of the high-performance membrane dialyzer. Contrib Nephrol. 2011;173:58–69
- Boudville N, Horner M, McEwan E, Lim WH, Mudge DW, Markus HE. Effect of FX dialyzers on systemic inflammation and quality of life in chronic hemodialysis patients. Blood Purif. 2009;27:187–193
- Chu PL, Chiu YL, Lin JW, Chen SI, Wu KD. Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance. Blood Purif. 2008;26:213–220
- Zhang DL, Liu J, Cui WY, Ji DY, Zhang Y, Liu WH. Differences in bio-incompatibility among four biocompatible dialyzer membranes using in maintenance hemodialysis patients. Ren Fail. 2011;33(7):682–691
- Beck W, Techert F, Lebsanft H, et al. Treatment frequency and efficiency in hemodiafiltration. Blood Purif. 2013;35(1–3):224–229
- Kantartzi K, Panagoutsos S, Mourvati E, et al. Can dialysis modality influence quality of life in chronic hemodialysis patients? Low-flux hemodialysis versus high-flux hemodiafiltration: a cross-over study. Ren Fail. 2013;35(2):216–221
- Pimenta J, Sampaio F, Martins P, et al. Aminoterminal B-type natriuretic peptide (NT-proBNP) in end-stage renal failure patients on regular hemodialysis: does it have diagnostic and prognostic implications? Nephron Clin Pract. 2009;111(3):182–188
- Sivalingam M, Suresh M, Farrington K. Comparison of B-type natriuretic peptide and NT proBNP as predictors of survival in patients on high-flux hemodialysis and hemodiafiltration. Hemodial Int. 2011;15(3):359–365
- Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221–228
- Oates T, Pinney JH, Davenport A. Hemodiafiltration versus high-flux hemodialysis: effects on phosphate control and erythropoietin response. Am J Nephrol. 2011;33(1):70–75
- Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int. 2005;68(5):2323–2330
- Schneider A, Drechsler C, Krane V, et al. The effect of high-flux hemodialysis on hemoglobin concentrations in patients with CKD: results of the MINOXIS study. Clin J Am Soc Nephrol. 2012;7(1):52–59
- Ayli D, Ayli M, Azak A, et al. The effect of high-flux hemodialysis on renal anemia. J Nephrol. 2004;17(5):701–706